Weekly Recap | JD HEALTH -3.47%, most brokers rate it buy
Weekly Review·- JD Health accumulated a 3.47 % decline this week to close at 35.08 HKD, underperforming the Hang Seng Index by about 1.34 percentage points amid overall weak market sentiment. - As of 2026-09-22, 18 institutions covered the company with a consensus rating of strong buy and a target price of 68.59 HKD, ranking first in the pharmaceutical retailer industry. - Future market focus centers on whether the weak trend will continue and if the stock price can stabilize within the 34 to 36 HKD range.Weekly Recap | MEITUAN -3.18%, consensus target above spot
Weekly Review·- This week, Meituan-W closed at 71.65 HKD, recording a cumulative weekly decline of 3.18% and underperforming the Hang Seng Index by 1.05 percentage points on shrinking trading volume. - Corporate developments during the week involved regulatory cooperation regarding travel operations alongside business expansions such as drone routes and AI product launches. - A total of 38 institutions maintained a consensus buy rating with an average target price of 110.57 HKD, reflecting significant divergence in valuation perspectives amid low stock prices.Weekly Recap | SENSETIME-W -0.4%, consensus target above spot
Weekly Review·- Sense - W closed at 1.26 HKD down 0.4% this week with a total amplitude of 7.81% and a lower trading volume than the 60 - day median. - JPMorgan initiated coverage on Sense - W with an overweight rating and a projected compound annual revenue growth rate of 28% for 2026 to 2028. - Nine institutions provided an overall buy rating with a consensus target price of 2.163 HKD which is approximately 71.68% higher than the current price.